Susan M. Chang

Susan M. Chang

Auto-generated profile, based on publicly available information

Susan M. Chang

Department of Neurological Surgery, University of California at San Francisco , San Francisco, California, (S.M.C.)

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 July 2025 in The Lancet Oncology
Verified
Journal Article
Open access
NGNorbert Galldiks
Norbert Galldiks
PLPhilipp Lohmann
Philipp Lohmann
MAMariam Aboian
Mariam Aboian
RJRamon Barajas Jr.
Ramon Barajas Jr.
WBWilliam G Breen
William G Breen
NANathalie L. Albert
Nathalie L. Albert
This Policy Review provides recommendations for the use of PET imaging in patients with gliomas and represents a joint effort of the Response Assessment in Neuro-Oncology (RANO) working group for PET and the European Association for Neuro-Oncology. The initial guideline was published in 2016, and summarised the previously established clinical benefit of PET with radiolabelled glucose and amino acid tracers in patients with gliomas. Since then, numerous additional studies have been published on this topic, focusing on differential diagnosis, prediction of molecular information, and prognostication. Further studies evaluated PET for biopsy guidance and delineation of glioma extent for local therapy planning, including resection and radiotherapy. In patients undergoing treatment, PET was studied for the assessment of response to local and systemic treatments and PET-based standardised response criteria (PET RANO 1.0) were proposed. In this Policy Review, the updated recommendations are based on evidence generated from studies that validated PET findings by histomolecular findings or clinical course. This guideline further underscores the previously reported clinical value of PET imaging and the superiority of amino acid PET over glucose PET, providing a framework for the use of PET in the management of patients with gliomas. The guideline also underscores the scarcity of class 1 evidence showing that incorporating PET imaging into clinical workflows improves patient outcomes, highlighting priority areas for future clinical studies designed to address this gap.

14 March 2025 in Science Advances
Verified
Journal Article
Open access
QWQixuan Wang
Qixuan Wang
JWJuan Wang
Juan Wang
RMRadhika Mathur
Radhika Mathur
MYMark W. Youngblood
Mark W. Youngblood
QJQiushi Jin
Qiushi Jin
FYFeng Yue
Feng Yue
Glioblastoma (GBM) is the most prevalent malignant brain tumor with poor prognosis. Although chromatin intratumoral heterogeneity is a characteristic feature of GBM, most current studies are conducted at a single tumor site. To investigate the GBM-specific 3D genome organization and its heterogeneity, we conducted Hi-C experiments in 21 GBM samples from nine patients, along with three normal brain samples. We identified genome subcompartmentalization and chromatin interactions specific to GBM, as well as extensive intertumoral and intratumoral heterogeneity at these levels. We identified copy number variants (CNVs) and structural variations (SVs) and demonstrated how they disrupted 3D genome structures. SVs could not only induce enhancer hijacking but also cause the loss of enhancers to the same gene, both of which contributed to gene dysregulation. Our findings provide insights into the GBM-specific 3D genome organization and the intratumoral heterogeneity of this organization and open avenues for understanding this devastating disease.

1 July 2024 in Radiology: Artificial Intelligence
Verified
Journal Article
Closed access
Brandon K.K. FieldsBrandon K.K. Fields
Brandon K.K. Fields
ECEvan Calabrese
Evan Calabrese
JMJohn Mongan
John Mongan
SCSoonmee Cha
Soonmee Cha
CHChristopher P. Hess
Christopher P. Hess
JRJeffrey D. Rudie
Jeffrey D. Rudie
"Just Accepted" papers have undergone full peer review and have been accepted for publication in Radiology: Artificial Intelligence. This article will undergo copyediting, layout, and proof review before it is published in its final version. Please note that during production of the final copyedited article, errors may be discovered which could affect the content. The University of California San Francisco Adult Longitudinal Post-Treatment Diffuse Glioma (UCSF-ALPTDG) MRI dataset is a publicly available annotated dataset featuring multimodal brain MRIs from 298 patients with diffuse gliomas taken at two consecutive follow-ups (596 scans total), with corresponding clinical history and expert voxelwise annotations. ©RSNA, 2024.

5 March 2025 in American Journal of Neuroradiology
Verified
Journal Article
Closed access
AAAdam Autry
Adam Autry
YKYaewon Kim
Yaewon Kim
DDDuy Dang
Duy Dang
HCHsin-Yu Chen
Hsin-Yu Chen
JSJames B. Slater
James B. Slater
SCSusan M. Chang
Susan M. Chang
Hyperpolarized carbon-13 (HP-13C) MRI enables the real-time measurement of dynamic metabolism by utilizing molecular probes whose magnetization has been transiently enhanced via dynamic nuclear polarization of 13C labels. Based on pre-clinical and clinical investigations demonstrating Warburg-related metabolic dysfunction and tricarboxylic acid (TCA)-cycle alterations in gliomas, HP13C techniques appear very promising for overcoming conventional challenges to evaluating tumor burden and extent, early therapeutic response and progression among patients non-invasively. This article surveys the multi-faceted translational development of HP-13C MRI in the context of glioma imaging, while emphasizing innovation concerning the pharmacy production of HP probes - [1-13C]/[2-13C]-pyruvate and [1-13C,5-12C]-alpha-ketoglutarate - that serve as non-radioactive metabolic contrast agents. Borrowing from practical experience, we present specific probe indications for isocitrate dehydrogenase (IDH)-wildtype glioblastomas and IDH-mutant gliomas together with example data to show the targeted, pathway-dependent function of these agents and their utility. Additional information pertaining to HP-13C hardware, acquisition and post-processing techniques provides an overview of the imaging methodology as it is currently performed at a leading institution. Considering the developing markers for progressive disease in glioblastomas and rapidly advancing capability, this unique imaging technology appears poised for translational impact following further evaluation.ABBREVIATIONS: 2-HG = D-2-hydroxyglutarate; α-KG = alpha-ketoglutarate; CSI = chemical shift imaging; d-DNP = dissolution-dynamic nuclear polarization; EPI = echo-planar imaging; EPSI = echo-planar spectroscopic imaging; IDHm = isocitrate dehydrogenasemutant; IR-SPGR = inversion recovery-prepared fast spoiled gradient-recalled (imaging); LrGGs = lower-grade gliomas; NMR = nuclear magnetic resonance; OGC = oxoglutarate carrier; PHIP = parahydrogen-induced polarization; SNR = signal-to-noise ratio; TCA cycle = tricarboxylic acid cycle; WHO = World Health Organization.

6 June 2025 in Science Advances
Verified
Journal Article
Open access
MMMulki Mehari
Mulki Mehari
GWGayathri Warrier
Gayathri Warrier
ADAbraham Dada
Abraham Dada
AKAymen Kabir
Aymen Kabir
AHAden P. Haskell-Mendoza
Aden P. Haskell-Mendoza
SHShawn Hervey-Jumper
Shawn Hervey-Jumper
Therapeutic clinical trial enrollment does not match glioma incidence across demographics. Traditional statistical methods have identified independent predictors of trial enrollment; however, our understanding of the interactions between these factors remains limited. To test the interactive effects of demographic, socioeconomic, and oncologic variables on trial enrollment, we designed boosted neural networks (BNNs) for all glioma patients ( n = 1042), women ( n = 445, 42.7%), and minorities ( n = 151, 14.5%) and externally validated these models [whole cohort, n = 230; women, n = 89 (38.7%); minority, n = 66 (28.7%)]. For the whole-cohort BNN, the most influential variables on enrollment were oncologic variables, including KPS [total effect (TE), 0.327], chemotherapy (TE, 0.326), tumor location (TE, 0.322), and seizures (TE, 0.239). The women-only BNN exhibited a similar trend. Conversely, for the minority-only BNN, socioeconomic variables [insurance status (TE, 0.213), occupation classification (TE, 0.204), and employment status (TE, 0.150)] were most influential. These results may help prioritize patient-specific initiatives to increase accrual.

8 June 2026 in Neuro-Oncology
Verified
Journal Article
Closed access
KSKarisa C. Schreck
Karisa C. Schreck
MFMacarena De la Fuente
Macarena De la Fuente
MLMary Jane Lim-Fat
Mary Jane Lim-Fat
SMSilvana Maas
Silvana Maas
JLJean M Mulcahy Levy
Jean M Mulcahy Levy
MGMarjolein Geurts
Marjolein Geurts
Oncogenic BRAF alterations occur in a subset of diffuse gliomas across WHO grades and are increasingly identified through modern molecular diagnostics. In addition to standard glioma therapies, targeted treatments are available for patients with BRAF-altered glioma, supported by variable evidence spanning randomized trials, single-arm studies, and real-world evidence. This joint consensus review from the Society for Neuro-Oncology (SNO) and the European Association of Neuro-Oncology (EANO) synthesizes current knowledge on the diagnosis and management of BRAF-altered gliomas across age groups, tumor grades, and lines of therapy. Particular emphasis is placed on expert consensus in clinical scenarios where high-quality trial evidence remains limited. The review addresses rationale testing for BRAF alterations, selection, and monitoring of targeted therapies, management of treatment-related toxicities, approaches to resistance, and priorities for future research. It aims to provide practical, evidence-based guidance for clinicians while highlighting gaps to inform prospective studies.